Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Authors
Keywords
-
Journal
LANCET
Volume 399, Issue 10319, Pages 36-49
Publisher
Elsevier BV
Online
2021-12-07
DOI
10.1016/s0140-6736(21)02718-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
- (2021) Robert H Shaw et al. LANCET
- India’s COVID-vaccine woes — by the numbers
- (2021) T. V. Padma NATURE
- Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays
- (2021) Kevin R. Bewley et al. Nature Protocols
- COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
- (2021) Muge Cevik et al. CELL
- Heterologous ChAdOx1-S/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2
- (2021) Chloé Dimeglio et al. CLINICAL INFECTIOUS DISEASES
- Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
- (2021) Annabel A Powell et al. Eurosurveillance
- To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination
- (2021) Nan-Chang Chiu et al. Expert Review of Vaccines
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
- (2021) Xinxue Liu et al. LANCET
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2021) Alberto M Borobia et al. LANCET
- Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
- (2021) Matthias Tenbusch et al. LANCET INFECTIOUS DISEASES
- Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
- (2021) Tina Schmidt et al. NATURE MEDICINE
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- (2021) Paul T. Heath et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
- (2021) Johan Normark et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
- (2021) David Hillus et al. Lancet Respiratory Medicine
- An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
- (2021) Alexandre Vallée et al. Journal of Clinical Medicine
- SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
- (2021) Daryl Geers et al. Science Immunology
- Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
- (2021) Louise Benning et al. Vaccines
- mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects
- (2021) Dorit Fabricius et al. Vaccines
- Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
- (2021) Rebecca P. Payne et al. CELL
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
- (2021) Alasdair P S Munro et al. LANCET
- Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
- (2021) Bruno Pozzetto et al. NATURE
- Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
- (2020) Yanchun Peng et al. NATURE IMMUNOLOGY
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search